Skip to main content
Premium Trial:

Request an Annual Quote

FDA Grants Emergency Use Authorizations for Altona, Diatherix Eurofins Coronavirus Tests

NEW YORK — The US Food and Drug Administration on Wednesday granted separate Emergency Use Authorizations for PCR-based SARS-CoV-2 tests developed by Altona Diagnostics and Diatherix Eurofins.

Altona's RealStar SARS-CoV-2 RT-PCR Kit US is designed to detect viral nucleic acid in nasopharyngeal swabs, oropharyngeal swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasal washes, and nasal aspirates. It runs on any authorized RT-PCR instrument and may be performed by labs CLIA-certified for high-complexity testing.

Diatherix's SARS-CoV-2 Assay is designed to detect viral nucleic acid in nasal swabs, nasopharyngeal swabs/wash, oropharyngeal swabs/throat swabs, bronchial aspirates, or sputum. It has been validated for use with Thermo Fisher Scientific's KingFisher Flex System using either Qiagen's ClearMag or Omega Bio-tek's Mag-Bind extraction reagents. The test can also be performed on the Thermo Fisher's Applied Biosystems GeneAmp 9700 or Veriti 96-well Thermal Cycler, the FDA said.

Diatherix's test may only be performed by its own laboratory.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.